MiNK Therapeutics doses first patient in phase 2 lung injury trial

May 28, 2026 9:05 AM

MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found